Automation from production through testing
Cell Shuttle automates end-to-end cell therapy production in a closed system. Cell Q handles in-process and release testing, allowing manufacturing and quality control to run together across the company’s factory network.
Preparing for commercial supply
Cellares expects to support clinical manufacturing in the first half of 2026. A $380 million agreement with Bristol Myers Squibb reserves commercial capacity in the United States, Europe and Japan. The financing brings total capital raised to $612 million.